

Review Article

Global Prevalence of *Yersinia enterocolitica* in Cases of Gastroenteritis: A Systematic Review and Meta-Analysis

Seyed Mohammad Riahi^[b],¹ Ehsan Ahmadi^[b],² and Tayebeh Zeinali^[b]

¹Cardiovascular Diseases Research Center, Department of Epidemiology and Biostatistics, Birjand University of Medical Sciences, Birjand, Iran

²Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
 ³Social Determinants of Health Research Center, Department of Public Health, School of Health, Birjand University of Medical Sciences, Birjand, Iran

Correspondence should be addressed to Tayebeh Zeinali; ta.zeinaly@gmail.com

Received 27 April 2021; Revised 15 August 2021; Accepted 23 August 2021; Published 3 September 2021

Academic Editor: Luigi Santacroce

Copyright © 2021 Seyed Mohammad Riahi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The prevalence of *Yersinia enterocolitica* in gastroenteritis is often underestimated. It relates considerably to morbidity and medical expenses around the world. Understanding the cause of gastroenteritis leads to making the appropriate treatment decisions. We systematically searched PubMed, Science Direct, Embase, and Scopus to identify all published studies between Jan. 1, 2000, and Dec. 31, 2019, to assess the prevalence of *Y. enterocolitica* in gastroenteritis patients. A total of 5039 articles were identified that lead to the extraction of data from 47 of them. The pooled prevalence of *Y. enterocolitica* in cases of gastroenteritis was estimated as 1.97% (1.32–2.74%) in the culture method and 2.41% (1.07–4.22%) in the molecular method. Among the biotypes of *Y. enterocolitica*, 1A (62.48%) and 1B (2.14%) had the most and least prevalence, respectively. Serotype O3 *Y. enterocolitica* with 39.46% had the highest and O5,27 with 0.0% had the least prevalence in gastroenteritis cases. In conclusion, the findings of this systematic review show that *Y. enterocolitica* is prevalent in gastroenteritis in all age groups. Serotypes O3 and O9 of *Y. enterocolitica* had the highest prevalence and O5,27 had the least prevalence in diarrheal patients. The prevalence of *Y. enterocolitica* was similar in both gender and different seasons. It should be noted that to determine the role of the organism, more studies are needed especially in food-borne diseases.

1. Background

Yersiniosis is caused by Gram-negative bacteria Yersinia enterocolitica (Y. enterocolitica) and Y. pseudotuberculosis. Although Y. enterocolitica is a frequent cause of human infection especially in developed countries of temperate zones, Y. pseudotuberculosis human infection is rare [1]. It mainly caused a gastrointestinal infection in humans. Additionally, Y. enterocolitica can cause other clinical manifestations including mesenteric lymphadenitis, endocarditis, and predominantly infects children [2]. Yersiniosis is the third cause of notifiable bacterial zoonosis in the European Union after campylobacteriosis and salmonellosis [3]. Y. enterocolitica is a psychrotrophic organism that can replicate at temperatures ranging from 0 to 44°C. As such, the organism can replicate in the refrigerator and survives in frozen foods and liquids for long periods. Peritrichous flagella causes the motility of Y. enterocolitica. Motility is temperature dependent, as the bacterium is motile at 25°C but is not motile when it grows at 37°C. Pathogenesis of Y. enterocolitica also depends on temperature. The invasive proteins of Y. enterocolitica produce at environmental temperatures of less than 28°C and under acidic conditions at 37°C. The expression of virulence factors necessary to infection initiates by the gradual increase of temperature within the host [2]. Infections caused by Y. enterocolitica pathogenic strains do not belong to a specific age group, but the clinical manifestation is frequently observed in children and younger adults. Adults can be asymptomatic carriers of infection [4]. Fever, abdominal pain, and diarrhea are the common symptoms of yersiniosis in children [2]. The bacterium was isolated from domestic and wild animals. Pigs are regarded as the reservoir of the pathogen [5], but high titers of anti-Yersinia antibodies in domestic animals, such as cattle, goats, and sheep revealed that there are other possible sources [6]. The main method of human infection is through consumption of contaminated food especially raw or undercooked ones [2] though drinking of contaminated water, close exposure to pet animals, and blood transfusion have also been mentioned [2, 7]. Y. enterocolitica had several biotypes and serotypes. Virulent isolates of Y. enterocolitica are attributed to certain biotypes and serotypes. Among the six known biotypes (including 1A, 1B, 2, 3, 4, and 5), 1A is reported as an nonpathogenic biotype in healthy people. Y. enterocolitica serotypes O3, O8, O9, and O5. 27 were isolated from most cases of human versiniosis [2]. The most serious disease is caused by serotype O8 with extensive ulceration of the gastrointestinal tract and sometimes death of the patients [8].

Patients may defecate Y. enterocolitica for 90 days after the recovery, which shows the importance of early detection of the bacterium in order to prevent transmission and possible outbreak [9]. In order to detect the Y. enterocolitica, a culture method and molecular assays were developed. The conventional culture method is time-consuming and has false-negative results while PCR is not only a sensitive and specific detection method but also is able to identify the pathogenic isolates and further characterization of the isolates [4]. Around the world, there is limited information about the prevalence of yersiniosis due to the clinical presentation of the disease as gastroenteritis so the diagnosis and treatment mainly depend on the clinicians and not on the microbiological culture. The aim of the present study was to estimate the global prevalence of versiniosis in cases of gastroenteritis. Moreover, the main biotypes and serotypes were determined. The existing data and knowledge were synthesized through a systematic literature review and metaanalysis.

2. Methods

2.1. Search Strategy and Study Selection. A systematic review was performed in PubMed, Science Direct, Embase, and Scopus to identify all published studies between Jan 1, 2000, and Dec 31, 2019, with the search keywords of "gastroenteritis," "*Yersinia enterocolitica*," and "yersiniosis" and related terms without any language restriction. The searched keywords were extracted from the Medical Subject Headings thesaurus. The search strategy was presented in the supplementary file. Titles and abstracts of relevant original articles after the removal of duplicates were screened by two independent reviewers (TZ and EA). The bibliographies of the included articles were hand-searched for additional references. Gray literature was searched by using Google Scholar. PRISMA guidelines were used to perform the systematic reviews.

Selection of studies was carried out by the following criteria: primary research studies including original article either published or in press; studies with a cross-sectional design; case group of case-control studies; studies including detection of *Y. enterocolitica* on the samples based on culture or PCR; patients having the symptoms of gastroenteritis; studies performed in a specified region or country; having a known number of sample size; and studies with available full texts. Studies with confusing text or incomprehensible analyses that did not report the sample size and number or percent of positive cases toward *Y. enterocolitica* were excluded. Reviews, letters, or editorial articles without original data were also excluded.

2.2. Data Extraction and Risk of Bias Assessment. A standard dedicated data extraction form was designed in Excel software. Two authors (TZ and SMR) extracted data independently. If provided, the following data were extracted from each study: bibliographic characteristics, including first author, year of publication, start and end year of the study, study design (cross-sectional or case-control), and country (income, HDI and WHO region); population characteristics, including the age of the participants (mean ± standard deviation (SD), minimum and maximum), gender, and total number of tested patients; methodological information, including diagnostic method, number of patients positive for Y. enterocolitica in culture and PCR separately, season of sampling, biotypes and some prevalent pathogenic serotypes of isolated Y. enterocolitica, and geographic location (latitude and longitude). We included samples with both Y. enterocolitica and another pathogen detected (e.g., E. coli or viruses).

Data were stratified by the diagnostic method and age. Regarding age, data were stratified into four categories: younger than 6 years, 6 to 18 years old, 18 to 59 years old, and more than 60 years old. As an indicator of development and epidemiological context, income, WHO region, and human development index were used to categorize the data on the basis of the country in which the study was performed. The eligible studies were qualified independently by two authors (TZ and EA) according to the Joanna Briggs Institute [10].

2.3. Statistical Analysis. In the current study, random-effect models were used for estimating pooled prevalence and 95% confidence intervals (95% CI). Metaprop command was used in Stata software. Pooled prevalence was calculated using a Freeman-Tukey double arcsine transformation [11, 12]. Heterogeneity among studies was examined by I^2 , Cochran's Q. I2 index ranges between 0 and 100 percent and I^2 > 70% was considered heterogeneous [13, 14]. A Forest plot in the random-effects model was applied to show pooled prevalence. Subgroup analysis and metaregression were done to identify the sources of heterogeneity [15]. Univariate metaregression analysis was used for assessing the effect of publication year, human development index, geographical location (longitude/latitude), and quality score on the prevalence of Y. enterocolitica. In a subgroup analysis, we estimated the prevalence of Y. enterocolitica in different age groups, type of diagnostic method, study's type, income, and WHO regions. Publication bias was not examined because



FIGURE 1: Flowchart of identification and selection of studies for inclusion in the review.

the aim of the study is not to determine the association between exposures and outcome [15]. The significance level was considered 0.05 in all analyses. All analyses were done by using STATA 13 (STATA Corp., College Station, Texas). In the metaregression, p value <0.1 was considered as a significant level due to the little range of prevalence of *Y. enterocolitica* and the rare nature of the organism.

3. Results

3.1. Study Characteristics. A total of 5039 articles were identified of which 4845 were not duplicates. According to the title and abstract, 202 articles were included and assessed for eligibility by full texts (Figure 1). From these, 49 articles passed the quality assessment and data were extracted from 47 of them. The final extracted data included 25 countries from all WHO regions (eight from the Americas, 17 from Europe, ten from Eastern Mediterranean, five from Africa, and seven from Western Pacific) except for the South-East Asia region. From these 47 studies, the prevalence of *Y. enterocolitica* by culture diagnosis method in cases of gastroenteritis was estimated as 1.97% (95% CI 1.32–2.74; $I^2 = 99.19\%$; p < 0.09 test for heterogeneity) (Figure 2(a)). However, by the PCR method the estimate of pooled

prevalence for *Y. enterocolitica* was 2.41 (95% CI 1.07–4.22; $I^2 = 98.39\%$; p < 0.00 test for heterogeneity (Figure 2(b)). There was significant heterogeneity among the included studies. Table 1 shows the pooled prevalence of *Y. enterocolitica* by culture and PCR method according to the countries. The highest prevalence of *Y. enterocolitica* in culture and PCR method was in Madagascar (16.56%). The lowest prevalence of *Y. enterocolitica* in culture and PCR method was in Australia (0.00%) and Brazil (0.00%), respectively. Table 2 shows the main characteristics of the included studies.

3.2. Subgroup Analysis. The type of study did not change the pooled prevalence of *Y. enterocolitica*, as in the culture method, the pooled prevalence in the cross-sectional and case-control studies is 2.20 and 1.22, respectively (random test for heterogeneity p < 0.12) (Figure 3(a)). The pooled prevalence of *Y. enterocolitica* by the PCR method in the cross-sectional and case-control studies is 2.28 and 4.44, respectively (p < 0.05) (Figure 3(b)). The pooled prevalence of *Y. enterocolitica* was decreased by the increase in the income of the countries (p < 0.001). The pooled prevalence of *Y. enterocolitica* in low- and high-income countries was

Study		ES (95% CI)	Weight (%)
Americas			
Abdel-Haq, N.M. (2000,USA)	•	1.34 (1.13, 1.58)	2.42
Orlandi, P.P. (2001,Brazil)		0.77 (0.02, 4.21)	1.87
Torres, M.E. (2001, Uruguay)		0.45 (0.01, 2.46)	2.07
Talan, D.A. $(2001, USA)$		0.73(0.20, 1.85) 1.70(1.17, 2.61)	2.27
Abdel-Hag, N.M. (2006,USA)		10 47 (9 13, 11 93)	2.30
Vernacchio, L. (2006,USA)	▲-	0.23 (0.01, 1.25)	2.23
Assis, F.E.A. (2014, Brazil)	• I	0.00 (0.00, 0.92)	2.21
Subtotal ($I^2 = 97.96\%$, $p = 0.00$)	\diamond	1.29 (0.11, 3.51)	17.82
Europe			
Svenungsson, B. (2000, Sweden)		0.24 (0.03, 0.85)	2 2 2
Maltezou H.C. (2001 Greece)		1.52(0.18, 5.37)	1.88
de Wit, M.A.S. (2001, Netherlands)		0.70 (0.26, 1.52)	2.32
Maraki, S. (2003,Greece)		0.65 (0.48, 0.86)	2.41
Olesen, B. (2005, Denmark)		2.36 (1.14, 4.29)	2.22
Huhulescu, S. (2007,Austria)	◆ 1	0.33 (0.01, 1.81)	2.16
Iernhag, A. (2008, Sweden)		5.04(4.91, 5.18)	2.43
Bucher M (2008 Germany)		0.20(0.15, 0.27)	2 42
Sihvonen, L.M. (2009,Finland)		1.13(1.03, 1.24)	2.42
Karsten, C. (2009,Germany)		0.96 (0.46, 1.75)	2.34
Huovinen, E. (2010,Finland)		0.97 (0.88, 1.07)	2.42
Gijsbers, C.F.M. (2011, Netherlands)	★ +	0.45 (0.01, 2.51)	2.07
Hilmarsdttir,I. (2012,Iceland)		0.65 (0.13, 1.88)	2.24
Stephen, R. (2013,Switzerland)		1.11(0.51, 2.10)	2.32
Calderaro, A (2018,Italy)		0.64(0.32, 1.14)	2.37
Subtotal $(I^2 = 99.64\%, p = 0.00)$		1.10 (0.36, 2.18)	37.88
Eastern mediterranian			
Nimmi I E and Maadam (2004 Jandan)		4 44 (1 04 9 57)	2.00
Soltan Dallal M M (2004 Iran)		4.44(1.94, 8.57) 2.67 (1.16, 5.19)	2.00
Soltan Dallal, M.M. (2006, Iran)		0.69 (0.34, 1.23)	2.37
Perdikogianni, C. (2006,Crete)		5.53 (4.34, 6.92)	2.36
Soleymani-Rahbar, A.A. (2007,Iran)		1.75 (0.96, 2.92)	2.32
Garveriani, E. (2007,Iran)		3.21 (1.72, 5.43)	2.22
Al Jarousha, A.M.Kh. (2011, Palestine)		2.67(1.16, 5.19)	2.15
El Qouqa, I.A. (2011, Palestine)		2.67 (1.55, 4.29) 2.71 (1.41, 4.41)	2.28
Subtotal $(I = 90.42\%, p = 0.00)$		2.71 (1.41, 4.41)	17.04
Africa			
GASCO' N, J. (2000, Tanzania)	<u> </u>	0.00 (0.00, 3.52)	1.77
Omoigberale, A.I. (2002, Nigeria)	· · · · · · · · · · · · · · · · · · ·	21.86 (16.53, 27.99)	2.06
Okwori, A.E.J. (2007, Nigeria)		4.00 (1.48, 8.50)	1.93
Bublitz, D.C. (2014, Madagascar)		16.56 (11.21, 23.18)	1.96
Subtotal $(I^2 = 94.85\%, p = 0.00)$		7.60 (1.89, 16.44)	9.97
Western Pacific			
Ebara A (2000 Japan)		202 (100 122)	2 22
Sinclare M I (2005 Australia)		2.92 (1.88, 4.32)	2.32
Zheng, H. (2007, China)		7.43 (5.60, 9.63)	2.30
Zheng, H. (2008, China)	*	6.15 (5.26, 7.15)	2.39
Wang, X. (2010,China)		1.22 (0.67, 2.03)	2.35
Wang, X. (2015, China)	•	0.28 (0.13, 0.53)	2.40
Duan, R. (2017,China)		0.87 (0.69, 1.08)	2.42
Subtotal ($I^2 = 98.38\%, p = 0.00$)		1.90 (0.54, 4.03)	16.49
Heterogeneity between groups: $p = 0.089$			
Overall $(I^2 = 99.19\%, p = 0.00);$	♦	1.97 (1.32, 2.74)	100.00
		1	
		45	
	v 15 50	43	
	Prevalence		
	(a)		

FIGURE 2: Continued.

International Journal of Microbiology



FIGURE 2: Forest plots for random-effects meta-analysis of the prevalence of *Y. enterocolitica* by (a) culture method and (b) PCR method in WHO regions.

Country		Culture		PCR
Country	Number	Pooled prevalence (95% confidence interval)	Number	Pooled prevalence (95% confidence interval)
Global	45	1.97 (1.32–2.74)	13	2.41 (1.07-4.22)
USA	5	2.09 (0.23-5.62)	1	0.23 (0.01-1.25)
Brazil	2	0.03 (0.00-0.53)	1	0.00 (0.00-0.92)
Uruguay	1	0.45 (0.01-2.46)	—	—
Sweden	2	4.95 (4.82-5.08)	—	—
Greece	2	0.50 (0.32-0.69)	—	—
Netherlands	2	0.60 (0.19–1.20)	—	—
Denmark	1	2.36 (1.14-4.29)	—	—
Austria	1	0.33 (0.01-1.81)	—	—
Germany	3	1.09 (0.05-3.11)	1	0.20 (0.15-0.27)
Finland	2	1.05 (0.98–1.12)	—	—
Iceland	1	0.65 (0.13-1.88)	—	—
Switzerland	1	1.11 (0.51-2.10)	_	_
Poland	1	2 (0.24-7.04)	1	2 (0.24–7.04)
Italy	1	0.64 (0.32-1.14)	1	0.99 (0.58–1.58)
Jordan	1	4.44 (1.94–8.57)	1	4.44 (1.94–8.57)

TABLE 1: A pooled prevalence of Y. enterocolitica by culture and PCR method according to the countries.

Country		Culture		PCR
Country	Number	Pooled prevalence (95% confidence interval)	Number	Pooled prevalence (95% confidence interval)
Iran	4	1.83 (0.75-3.35)	1	2.64 (1.37-4.56)
Crete	1	5.53 (4.34-6.92)	_	_
Saudi Arabia		_	1	0.00 (0.00-2.24)
Palestine	2	2.65 (1.68-3.83)	_	_
Tanzania	1	0.00 (0.00-3.52)	_	_
Nigeria	3	9.29 (1.94-3.08)	1	5.62 (3.74-8.08)
Madagascar	1	16.56 (11.21-23.18)	1	16.56 (11.21-23.18)
Japan	1	2.92 (1.88-4.32)	_	_
Australia	1	0.00 (0.00-0.47)	_	—
China	5	2.41 (0.61-5.35)	3	4.37 (0.54–11.54)

TABLE 1: Continued.

7.17 and 1.35 in culture (*p* < 0.001) (Figure 4(a)) and 16.56 and 0.36 in PCR method (p < 0.02) (Figure 4(b)), respectively. The source of heterogeneity of included studies is income. According to age, the prevalence was not significantly different in younger than 6 years, 6-18 years, and 18-59 years (1.75%; 0.96-2.54; p < 0.95 for culture and 1.84%; 0.49–3.19; p < 0.66 for PCR; $I^2 = 0.0\%$) (Figure 5(a)). By gender of participants and season of sampling, the prevalence was similar (p < 0.98 and p < 0.89, respectively) (Figure 5(a)). According to the biotype of Y. enterocolitica isolates, 1A (62.48%; 95% CI 27.56-91.77) and 1B (2.14%; 95% CI 0.04-6.14) had the most and least prevalence, respectively. Among the investigated serotypes of Y. enterocolitica isolates, O3 with 39.46% had the highest and O5,27 with 0.0% had the least prevalence (Figure 5(b)).

3.3. Metaregression. According to Figures 6(a) and 6(b), by the increase of publication year, the prevalence did not have any significant change (p < 0.51 for culture and p < 0.38 for PCR). Countries with higher HDI had a lower prevalence of *Y. enterocolitica* (p < 0.39 for culture and p < 0.01 for PCR) (Figures 6(c) and 6(d)). Longitude had not any significant effect on the prevalence of Y. enterocolitica (p < 0.7 for culture and p < 0.24 for PCR) (Figures 6(e) and 6(f)). The prevalence of Y. enterocolitica increased slightly with increasing latitude but was not statistically significant (p < 0.12) in the culture method; in contrast, its prevalence was decreased with the increasing latitude in the PCR method (p < 0.01) (Figures 6(g) and 6(h)). Metaregression for quality assessment and prevalence was carried out and no relation was observed (p < 0.74 for culture and p < 0.33 for PCR).

4. Discussion

In the current meta-analysis, we provided the first estimates of the global prevalence of yersiniosis in cases of gastroenteritis. Based on the culture isolation of *Y. enterocolitica*, Africa [1, 26, 39, 40, 44] and Eastern Mediterranean [17, 22, 42, 46, 48, 53, 56–58] WHO regions had the first and second rank of prevalence of the bacterium, while Europe [4, 16, 19, 21, 24–26, 28, 29, 33–36, 38, 45, 49, 50, 54] had the least prevalence of *Y. enterocolitica* in gastroenteritis cases.

Yersiniosis had a global prevalence and is a reportable disease in some countries, such as Denmark, Norway, and 38 states of USA [59, 60]. According to PCR detection, Africa and Western Pacific [3, 9, 18, 23, 27, 37] had the most, and the Americas [20, 30-32, 41, 51, 52, 55] had the least prevalence of Y. enterocolitica. In the present study, the highest prevalence of Y. enterocolitica in culture and PCR method was in Madagascar (16.56%). The lowest prevalence of Y. enterocolitica in culture and PCR method was in Australia (0.00%) and Brazil (0.00%), respectively, in the current study. Bublitz et al. (2014) reported that the prevalence of Y. enterocolitica is 16.56% in Madagascar and Assiss et al. (2014) reported it is 0.0% in Brazil. In the United States (US), 0.33 per 100000 individuals were infected by Yersinia during 1996 to 2012 in the general population according to Food-borne Diseases Active Surveillance Network, 2012 [61]. In Denmark, Y. enterocolitica was reported as a common cause of bacterial diarrheal disease with 4.9 cases per 100,000 inhabitants in 2016 [62]. Among developed countries, food-borne versiniosis was higher in most European countries than US [63, 64]. The prevalence of Y. enterocolitica was higher in gastroenteritis patients than in the general healthy population. In the present study, income was the origin of heterogeneity among included studies. As, in the low-income countries, Y. enterocolitica was more prevalent than high-income ones. This can be related to considering hygiene principles. Human yersiniosis is commonly caused by Y. enterocolitica [59]. Yersiniosis caused self-limiting diarrhea that sometimes may be bloody in children younger than four years old. However, fever and abdominal pain accompanied by diarrhea and/or vomiting were reported in older children and adults [9]. The clinical presentation of gastrointestinal disease can be different based on the age and immune status of the host [2]. Diagnosis of yersiniosis is done by isolation of the microbe from human feces or blood or following removal of the appendix, mistakenly [59], although the culture of the bacterium is not a usual procedure for gastrointestinal patients in most hospitals that may lead to underestimates of versiniosis [59].

Age was not a significant factor regarding gastroenteritis caused by *Y. enterocolitica* in the current study. Some studies reported that younger children are more susceptible to diarrhea caused by *Y. enterocolitica* [9, 27, 39, 40]. Al Jarousha TABLE 2: Characteristics of the included studies in the meta-analysis based on eligibility criteria.

			IABLE 2	: Unaracterist	ics of the in	cluded	studies ii	n the met	ca-analysis based on	eligibility criteri	a.		
Study	Publication_year	Start_year	End_year	Type of study	Country	Mean age	Min_age	Max_age	Diagnosis_method Tc	otal_sample_size To	otal_PCR_positive To	tal_culture_positive	Quality score
Calderaro et al. [16]	2018	2016	2018	Cross- sectional	Italy	3.6	0	14	Culture + PCR	1716	17	11	6
Hawash et al. [17]	2017	2016	2017	Cross- sectional	Saudi Arabia	29.9	0	60	PCR	163	0	I	10
Wang et al. [18]	2015	2010	2014	Cross- sectional	China	I	0	65	Culture	3224	I	6	6
Fiedoruk et al. [19]	2015	2010	2011	Cross- sectional	Poland		0	4	Culture + PCR	100	2	2	6
Assis et al. [20]	2014	2010	2011	Cross- sectional	Brazil	I	I	I	Culture + PCR	400	0	0	6
Hilmarsdóttir et al. [21]	2012	2003	2007	Cross- sectional	Iceland	I	0	83	Culture	464	I	З	10
El Qouqa et al. [22]	2011	2006	2007	Case-control	Palestine	5.01	0	12	Culture	600	I	16	6
Wang et al. [23]	2010	2004	2008	Cross- sectional	China	I	I	I	Culture	1152	I	14	8
Zheng et al. [9]	2008	2005	2008	Cross- sectional	China	I	0	83	Culture + real time PCR	2600	178	160	6
Maltezou et al. [24]	2001	1999	1999	Cross- sectional	Greece		0	14	Culture	132	I	2	×
Huhulescu et al. [25]	2007	2007	2009	Cross- sectional	Austria	37	0	89	Culture	306	Ι	1	10
Okwori et al. [1]	2009	2002	2004	Cross- sectional	Nigeria	I	18	I	Culture + PCR	480	27	27	6
Bucher et al. [4]	2008	2002	2002	Cross- sectional	Germany	I	I	I	Culture + real time PCR	22835	46	46	9
Bublitz et al. [26]	2014	2011	2011	Cross- sectional	Madagascar		0	15	Culture + PCR	163	27	27	10
Duan et al. [3]	2017	2010	2015	Cross- sectional	China	I	0	59	Culture + PCR	9208	80	80	10
Ehara et al. [27]	2000	1997	1999	Cross- sectional	Japan	3.56	0	14	Culture	821	I	24	~
Ternhag et al. [28]	2008	1997	2004	Cross- sectional	Sweden	36.5	0	100	Culture	101855	Ι	5133	~
Gijsbers et al. [29]	2011	2002	2004	Cross- sectional	Netherlands	8.8	4	16	Culture	220	I	1	9
Rees et al. [30]	2004	1998	1999	Cross- sectional	USA	I	I	72	Culture	1454	I	26	9
Vernacchio et al. [31]	2006	2001	2002	Case-control	USA	I	0	6	Culture + PCR	443	1	1	10
Talan et al. [32]	2001	1997	1998	Prospective case series	USA	2.9	4	41	Culture	549	I	4	6
de Wit et al. [33]	2001	1996	1999	Case-control	Netherlands	I	0	80	Culture	857	I	6	10
Karsten et al. [34]	2009	2004	2004	Case-control	Germany	I	0	80	Culture	1,046	ĺ	10	6
Svenungsson et al. [35]	2000	1996	1997	Case-control	Sweden	41	15	98	Culture	851	I	2	6
Olesen et al. [36]	2005	2000	2001	Case-control	Denmark	1.2	0	4	Culture	424	Ι	10	6

	Study	Publication_yea	r Start_year	End_year	Type of study	Country	Mean age	Min_age	Max_age	Diagnosis_method	Total_sample_siz	e Total_PC	R_positive Total	_culture_positive	Quality score
	Sinclair et al. [37]	2005	1997	1999	Cross- sectional	Australia	I	0	59	Culture	162			0	6
	Jansen et al. [38]	2008	2005	2007	Prospective cohort	Germany	48	18	16	Culture/serology	104	·	I	9	6
and Model and Model20022002003Cross actionalNgeria $$	Okwori. et al. [39]	2007	2005	2006	Cross- sectional	Nigeria	Ι	1	69	Culture	150	·	I	9	6
	Omoigberale and Abiodun [40]	2002	2001	2001	Cross- sectional	Nigeria	Ι	-	59	Culture	215	·	I	47	6
	Abdel-Haq et al. [41]	2006	1990	2002	Cross- sectional	NSA	10.3	0	14	Culture	1920	·	I	201	10
	Perdikogianni et al. [42]	2006	1993	2004	Cross- sectional	Crete	Ι	0	14	Culture	1285	·	I	71	Ŋ
Gase ot al. [44] 200 197 197 197 Case-control Tarzania - 0 5 Culture 103 - 1 3 Colsential 2013 2011 $\frac{Corsential}{Corsential}$ Iran - 20 60 Culture 811 - - - - 20 60 -	Zheng et al. [43]	2007	2005	2006	Cross- sectional	China	I	2	83	Culture + real time PCR	200	-,	52	52	10
Style 2013 2011 2013 Corss- corsinal Switzerland - 20 60 Culture 811 - - Garveriani et al. 2007 2005 2006 Cross- corsinal Iran - 0 5 Culture 813 - - Garveriani et al. 2007 2005 2006 Cross- corsinal Iran 5 0 12 Culture 415 -	Gasco et al. [44]	2000	1997	1997	Case-control	Tanzania	I	0	ß	Culture	103	·	I	0	6
	Stephen et al. [45]	2013	2011	2011	Cross- sectional	Switzerland		20	60	Culture	811	·	I	6	0
	Garveriani et al. [46]	2007	2005	2006	Cross- sectional	Iran	I	0	IJ	Culture	405	·	I	13	6
	GhasemiKebria et al. [47]	2010	2005	2006	Cross- sectional	Iran	5.07	0	22	PCR	455		12	I	6
Huovinen et al. (49)201020062006Case-controlFinland 46.66 099Culture 41841 -(49)200920062006Cross- sectionalFinlandCulture 41843 -(50)200119981999Cross- sectionalFinlandCulture 41843 -(51)200119981999Cross- sectionalUSA0.75012Culture 190 -(52)200119901997RetrospectiveUSA0.75012Culture 10570 (52)200119901997Cross-Greece-02Culture 100 8Meraki et al.200119901994Cross-Iran 48 128Culture 100 8Solar Dallal et al. [56]20061999Cross-Iran 3.24 02Culture 100 Solar Dallal et al. [57]20041999Cross-Iran 3.24 010-2Solar Dallal et al. [56]20051111111<	Al Jarousha et al. [48]	2011	2006	2007	Case-control	Palestine	5.01	0	12	Culture	300	I		8	6
Silvonen et al. [50]200920062006 $Cross-$ sectionalFinland $ -$ Culture41343 $-$ [51]00119981999Carse-controlBrazil0.3605Culture130 $-$ Orlandi et al. (51]200119901997RetrospectiveUSA0.75012Culture130 $-$ Abdel·Haq et al. (52)200419901997RetrospectiveUSA0.75012Culture + PCR180 $-$ 8Marabi et al. (54)200420002002Carse-controlJordan481284Culture + PCR180 $-$ 8Marabi et al. (54)200119902992Gross- fromIran $-$ 059Culture7090 $-$ Marabi et al. (54)200119901994Gross- fromIran $-$ 0 2 Culture7090 $-$ Soltan Dallal et al. [57]200419991999Gross- fromIran $-$ 0 2 Culture1600 $-$ Soltan Dallal et al. [57]200419991999Gross- fromIran $ 0$ 2 Culture 100 $-$ Soltan Dallal et al. [57]200419991999Gross- fromIran $ 0$ 2 Culture 100 $-$ Soltan Dallal et al. [57]200419991999	Huovinen et al. [49]	2010	2006	2006	Case-control	Finland	46.66	0	66	Culture	41841	Ι		406	8
	Sihvonen et al. [50]	2009	2006	2006	Cross- sectional	Finland	I	I	Ι	Culture	41848	Ι		473	4
	Orlandi et al. [51]	2001	1998	1999	Case-control	Brazil	0.86	0	5	Culture	130	I		1	10
	Abdel-Haq et al. [52]	2000	1990	1997	Retrospective	NSA	0.75	0	12	Culture	10 570	I		142	6
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Nimri and Meqdam [53]	2004	2000	2002	Case-control	Jordan	48	12	84	Culture + PCR	180		8	8	10
Torres et al. [55] 2001 1990 1994 Case-control Uruguay 0.4 0 2 Culture 224 - Dallal et al. [56] 2006 1998 1999 Cross- sectional Iran - 0 5 Culture 1600 - Soltan Dallal et al. [57] 2004 2002 2002 Cross- sectional Iran - 0 5 Culture 300 - Soltan Dallal 2004 2002 2002 Cross- sectional Iran 3.24 0 12 Culture 300 - Rabbar et al. 2007 - - Cross- sectional Iran - 0 10 Culture 800 - Fabbar et al. 2007 - - - 0 10 Culture 800 - Fabbar et al. 2007 - - - 0 10 Culture 800 - Fabbar et al. - - 0 10 Culture 800 -	Maraki et al. [54]	2003	1995	1999	Cross- sectional	Greece	I	0	59	Culture	2090	I		46	10
Dallal et al. [56] 2006 1998 1999 Cross- sectional Iran - 0 5 Culture 1600 - Soltan Dallal 2004 2002 2002 Cross- Gross- sectional Iran 3.24 0 12 Culture 300 - Soleymani- Fabbar et al. 2007 - - Cross- sectional Iran 3.24 0 12 Culture 300 - [58] - - - 0 10 Culture 800 -	Torres et al. [55]	2001	1990	1994	Case-control	Uruguay	0.4	0	2	Culture	224	I		1	8
Soltan Dallal 2004 2002 Cross- sectional Iran 3.24 0 12 Culture 300 - et al. [57] 2007 - - Cross- sectional Iran 3.24 0 12 Culture 300 - Rahbar et al. 2007 - - Cross- sectional Iran - 0 10 Culture 800 - [58] - - 0 10 Culture 800 -	Dallal et al. [56]	2006	1998	1999	Cross- sectional	Iran	I	0	ß	Culture	1600	I		11	10
Soleymani- Rahbar et al. 2007 — Cross- Isectional Iran — 0 10 Culture 800 — [58]	Soltan Dallal et al. [57]	2004	2002	2002	Cross- sectional	Iran	3.24	0	12	Culture	300	I		8	10
	Soleymani- Rahbar et al. [58]	2007	l	I	Cross- sectional	Iran	I	0	10	Culture	800	I		14	6

TABLE 2: Continued.

International Journal of Microbiology

Study				ES (95% CI)	Weight (%)
cross sectional	1				
bdel-Hag, N.M. (2000,USA)				1.34 (1.13, 1.58)	2.42
'alan, D.A. (2001,USA)				0.73 (0.20, 1.85)	2.27
ees, J.R. (2004,USA)	÷			1.79 (1.17, 2.61)	2.36
bdel-Haq, N.M. (2006,USA)	1 -	◆ -		10.47 (9.13, 11.93)	2.38
ernacchio, L. (2006,USA)	· ·	_		0.23 (0.01, 1.25)	2.23
ssis, F.E.A. (2014,Brazil)	•			0.00 (0.00, 0.92)	2.21
laltezou, H.C. (2001,Greece)	-			1.52 (0.18, 5.37)	1.88
Iaraki, S. (2003,Greece)	•			0.65 (0.48, 0.86)	2.41
uhulescu, S. (2007,Austria)	•			0.33 (0.01, 1.81)	2.16
ernhag, A. (2008,Sweden)				5.04 (4.91, 5.18)	2.43
nsen, A. (2008,Germany)				5.77 (2.15, 12.13)	1.77
ucher, M. (2008,Germany)				0.20 (0.15, 0.27)	2.42
hvonen, L.M. (2009,Finland)				1.13 (1.03, 1.24)	2.42
uovinen, E. (2010,Finland)	♦ 1			0.97 (0.88, 1.07)	2.42
ijsbers, C.F.M. (2011,Netherlands)	◆ -+			0.45 (0.01, 2.51)	2.07
ilmarsdttir,I. (2012,Iceland)	◆ !			0.65 (0.13, 1.88)	2.24
ephen, R. (2013,Switzerland)	.			1.11 (0.51, 2.10)	2.32
edoruk, K. (2015,Poland)	-			2.00 (0.24, 7.04)	1.75
alderaro, A. (2018,Italy)	•			0.64 (0.32, 1.14)	2.37
oltan Dallal, M.M. (2004,Iran)	-			2.67 (1.16, 5.19)	2.15
oltan Dallal, M.M. (2006,Iran)	•			0.69 (0.34, 1.23)	2.37
erdikogianni, C. (2006,Crete)				5.53 (4.34, 6.92)	2.36
oleymani-Rahbar, A.A. (2007,Iran)	-			1.75 (0.96, 2.92)	2.32
arveriani, E. (2007,Iran)				3.21 (1.72, 5.43)	2.22
moigberale, A.I. (2002,Nigeria)				21.86 (16.53, 27.99)	2.06
kwori, A.E.J. (2007,Nigeria)	•			4.00 (1.48, 8.50)	1.93
kwori, A.E.J. (2009,Nigeria)				5.63 (3.74, 8.08)	2.25
ublitz, D.C. (2014,Madagascar)	1	•	_	16.56 (11.21, 23.18)	1.96
hara, A. (2000,Japan)	++-			2.92 (1.88, 4.32)	2.32
nclare, M.I. (2005,Australia)	I			0.00 (0.00, 0.47)	2.31
heng, H. (2007,China)				7.43 (5.60, 9.63)	2.30
neng, H. (2008,China)				6.15 (5.26, 7.15)	2.39
ang, X. (2010,China)	◆			1.22 (0.67, 2.03)	2.35
ang, X. (2015,China)				0.28 (0.13, 0.53)	2.40
uan, R. (2017,China)				0.87 (0.69, 1.08)	2.42
btotal ($I^2 = 99.37\%$, $p = 0.00$)				2.20 (1.43, 3.11)	78.64
se-control					
rlandi, P.P. (2001,Brazil)	•			0.77 (0.02, 4.21)	1.87
orres, M.E. (2001,Uruguay)				0.45 (0.01, 2.46)	2.07
renungsson, B. (2000,Sweden)				0.24 (0.03, 0.85)	2.32
Wit, M.A.S. (2001, Netherlands)	◆ -			0.70 (0.26, 1.52)	2.32
lesen, B. (2005,Denmark)				2.36 (1.14, 4.29)	2.22
arsten, C. (2009,Germany)	•			0.96 (0.46, 1.75)	2.34
imri, L.F. and Meqdam (2004,Jordan)				4.44 (1.94, 8.57)	2.00
Jarousha, A.M.Kh. (2011,Palestine)				2.67 (1.16, 5.19)	2.15
Qouqa, I.A. (2011, Palestine)				2.67 (1.53, 4.29)	2.28
ASCO′ N, J. (2000,Tanzania)	♦ + -			0.00 (0.00, 3.52)	1.77
btotal ($I^2 = 77.15\%$, $p = 0.00$)	\diamond			1.22 (0.57, 2.08)	21.36
terogeneity between groups: $p = 0.12$	1				
verall $(I^2 = 99.19\%, p = 0.00);$				1.97 (1.32, 2.74)	100.00
	0	15	30	45	
	0	1.5	50	ч <i>л</i>	

(a)

FIGURE 3: Continued.



FIGURE 3: Forest plots for random-effects meta-analysis of the prevalence of *Y. enterocolitica* by (a) culture method and (b) PCR method according to the type of studies.

et al. reported higher isolation of Y. enterocolitica from diarrheic children with the age of one to six years than children less than one year and more than 6 years [48]. Y. enterocolitica had different biotypes and serotypes. The insignificant effect of age may be due to infection of children, adults, and the elderly with different serotypes that may not necessarily create immunity to other serotypes [65]. Furthermore, limited studies were performed on older ages. Gender difference was not seen in the current study. Men and women did not show different symptoms in yersiniosis [40, 49]. A seasonal variation was not seen in the present study. Some studies reported more cases during the cooler season [46, 66], but according to the report of the European Centre for Disease Prevention and Control, no seasonal pattern was observed for yersiniosis for a period of three years [67]. Some other studies did not also report a significant difference between seasons [9, 47, 68], which may support the hypothesis that the infection is transmitted via food items that are consumed consistently throughout the year, such as meat and meat products [65].

Among the six biotypes of *Y. enterocolitica*, 1A was the most prevalent biotype. As biotype 1A is a nonpathogenic biotype mostly found in the environment, it had a higher

prevalence in most studies and was isolated from human, animals, and gastroenteritis [49, 50, 69]. Among the virulent biotypes, biotypes II and III had a prevalence of 33.06% and 12.89%, respectively. In the current study, serotypes O3 and O9 had the most prevalence. They were reported in other studies as the main serotypes of Y. enterocolitica in diarrheal patients [4, 39, 43]. Serotype O8 was the third serotype in gastroenteritis patients of the current study. It was observed as the most pathogenic serotype in biotype 1B that was correlated to four of six food poisoning outbreaks in the US [41]. A total of 18% of the patients were infected with pathogenic Y. enterocolitica [49]. A total of 0.6% of acute diarrhea cases were because of Y. enterocolitica and all of them were serotype O3 [54]. In Nigeria, Y. enterocolitica bioserotype 2/O9 was the only isolated pathogenic in human samples. Bioserotype 4/O3 of Y. enterocolitica is the major isolated one from humans globally [63] and was isolated in some European countries, including Denmark, Italy, Belgium, Spain, Finland, and Sweden [50, 64]. According to Stephen et al., biotypes II and IV were only diagnosed in diarrheal patients, but strains of biotype 1A were isolated from both asymptomatic and diarrheal patients which shows the biotype 1A is not the etiologic agent of gastroenteritis [45]. Y. enterocolitica serotype O3 was commonly isolated

International Journal of Microbiology

Study				ES (95% CI)	Weight (%)
Low					
GASCO' N, J. (2000, Tanzania)				0.00 (0.00, 3.52)	1.77
Bublitz, D.C. (2014, Madagascar)		•		16.56 (11.21, 23.18)	1.96
Subtotal ($I^2 = 99.98\%, p = 0.00$)				7.17 (4.30, 10.65)	3.73
Lower_middle					
Omoigberale, A.I. (2002, Nigeria)		•		21.86 (16.53, 27.99)	2.06
Okwori, A.E.J. (2007,Nigeria)		_		4.00 (1.48, 8.50)	1.93
Okwori, A.E.J. (2009, Nigeria)	●			5.63 (3.74, 8.08)	2.25
El Qouqa, I.A. (2011,Palestine)				2.67 (1.53, 4.29)	2.28
Al Jarousha, A.M.Kh. (2011,Palestine)				2.67 (1.16, 5.19)	2.15
Subtotal ($I^2 = 94.46\%, p = 0.00$)				6.13 (2.07, 12.05)	10.67
Upper_middle					
Orlandi, P.P. (2001,Brazil)	•			0.77 (0.02, 4.21)	1.87
Nimri, L.F. and Meqdam (2004,Jordan)	• • • • • • • • • • • • • • • • • • •			4.44 (1.94, 8.57)	2.00
Soltan Dallal, M.M. (2004,Iran)	-			2.67 (1.16, 5.19)	2.15
Soltan Dallal, M.M. (2006,Iran)	◆			0.69 (0.34, 1.23)	2.37
Soleymani-Rahbar, A.A. (2007,Iran)	-			1.75 (0.96, 2.92)	2.32
Garveriani, E. (2007,Iran)	+ •			3.21 (1.72, 5.43)	2.22
Zheng, H. (2007, China)				7.43 (5.60, 9.63)	2.30
Zheng, H. (2008,China)	★			6.15 (5.26, 7.15)	2.39
Wang, X. (2010, China)				1.22 (0.67, 2.03)	2.35
Assis, F.E.A. (2014,Brazil)				0.00(0.00, 0.92)	2.21
Wang, A. (2015, China) Duan $\mathbb{P}_{2}(2017, China)$				0.28(0.13, 0.53) 0.87(0.69, 1.08)	2.40
Subtotal $(l^2 = 97.02\%, p = 0.00)$				1.89(0.83, 3.34)	26.99
High	Ĩ				
Summarian B (2000 Sundar)				0.24 (0.02, 0.85)	2.22
Abdel Hag NM (2000 USA)				0.24(0.05, 0.85) 1.34(1.13, 1.58)	2.52
Ebara A (2000 Janan)				2.92(1.88, 4.32)	2.42
Torres M F (2001 Uruguay)				0.45(0.01, 2.46)	2.52
Talan, D.A. (2001,USA)				0.73 (0.20, 1.85)	2.27
Maltezou, H.C. (2001,Greece)				1.52 (0.18, 5.37)	1.88
de Wit, M.A.S. (2001, Netherlands)	◆ - I			0.70 (0.26, 1.52)	2.32
Maraki, S. (2003, Greece)	♦ 1			0.65 (0.48, 0.86)	2.41
Rees, J.R. (2004,USA)	◆			1.79 (1.17, 2.61)	2.36
Sinclare, M.I. (2005, Australia)	▲			0.00 (0.00, 0.47)	2.31
Olesen, B. (2005, Denmark)				2.36 (1.14, 4.29)	2.22
Perdikogianni, C. (2006,Crete)	- • - · · · · · · · · · · · · · · · · ·			5.53 (4.34, 6.92)	2.36
Abdel-Haq, N.M. (2006,USA)				10.47 (9.13, 11.93)	2.38
Vernacchio, L. (2006, USA)				0.23(0.01, 1.25)	2.23
Temphag A (2008 Sweden)				0.33(0.01, 1.81)	2.10
Jansen A. (2008 Germany)				5 77 (2 15 12 13)	2.43
Bucher M (2008 Germany)				0.20(0.15, 0.27)	2 42
Sihvonen, I. M. (2009,Finland)				1 13 (1 03, 1 24)	2.12
Karsten, C. (2009,Germany)	•			0.96 (0.46, 1.75)	2.34
Huovinen, E. (2010,Finland)				0.97 (0.88, 1.07)	2.42
Gijsbers, C.F.M. (2011, Netherlands)	▲ ↓			0.45 (0.01, 2.51)	2.07
Hilmarsdttir,I. (2012,Iceland)	◆			0.65 (0.13, 1.88)	2.24
Stephen, R. (2013,Switzerland)	◆			1.11 (0.51, 2.10)	2.32
Fiedoruk, K. (2015,Poland)				2.00 (0.24, 7.04)	1.75
Calderaro, A. (2018,Italy)				0.64 (0.32, 1.14)	2.37
Subtotal ($I^2 = 99.48\%, p = 0.00$)				1.35 (0.68, 2.23)	58.60
Heterogeneity between groups: $p = 0.000$	1				
Overall ($I^2 = 99.19\%$, $p = 0.00$);	\diamond			1.97 (1.32, 2.74)	100.00
	<u> </u>			I	
	0	15	30	45	
		Prevalen	ce	-	
		1 Te - alein			

(a) FIGURE 4: Continued.



FIGURE 4: Forest plots for random-effects meta-analysis of the prevalence of *Y. enterocolitica* by (a) culture method and (b) PCR method according to income of countries.

Study ID	ES (95% CI)	Study ID		ES (95% CI)
Diagnois method, Culture <6 years old (n=21, 1^2 =94.01) 6-18 years old (n=2, 1^2 =93.72) 18-59 years old (n=9, 1^2 =93.28) Subtotal (l^2 = 0.0%, p = 0.952) Diagnois method, PCR <6 years old (n=7, 1^2 =96.1) 6-18 years old (n=5, 1^2 =90.57) 18-59 years old (n=4, 1^2 =96.08) Subtotal (l^2 = 0.0%, p = 0.662)	1.78 (0.89, 2.92) 1.87 (0.49, 3.94) 1.49 (0.14, 3.82) 1.75 (0.96, 2.54) 1.57 (0.24, 3.78) 3.18 (0.69, 7.09) 1.49 (0.01, 5.54) 1.84 (0.49, 3.19)	Biotype 1A (n=6, l^2 =98.92) II (n=8, l^2 =97.74) III (n=4, l^2 =98.2) IV (n=7, l^2 =92.93) V (n=2, l^2 =NA) 1B (n=2, l^2 =NA)		62.48 (27.56, 91.77) 33.06 (10.43, 59.89) 12.89 (0.00, 45.83) 7.46 (0.00, 23.83) 2.27 (0.07, 6.32) 2.14 (0.04, 6.14)
Gender Female (n=7, 1^2 =93.63) Male (n=7, 1^2 =90.44) Subtotal (l^2 = 0.0%, p = 0.987) Seasons Spring (n=8, 1^2 =84.21) Summer (n=7, 1^2 =54) Autumns (n=9, 1^2 =92.06) Winter (n=7, 1^2 =90.77) Subtotal (l^2 = 0.0%, p = 0.898) NOTE: Weights are from random effects analysis	4.60 (1.75, 8.61) 4.56 (1.78, 8.45) 4.58 (2.19, 6.97) 2.03 (0.62, 4.08) 1.79 (0.87, 2.97) 2.09 (0.47, 4.61) 2.98 (0.70, 6.52) 1.97 (1.18, 2.76)	Serotype O3 (n=11, 1^2 =96.01) O9 (n=12, 1^2 =96.54) O8 (n=7, 1^2 =83.22) O5 (n=5, 1^2 =79.92) O527 (n=4, 1^2 =0)		39.46 (17.61, 63.32) 30.81 (9.80, 55.99) 5.18 (0.00, 21.12) 0.92 (0.00, 11.72) 0.00 (0.00, 0.01)
	2 5 10 Prevalence (%)		0 25 50 75 Proportion (%)	

FIGURE 5: Forest plots for random-effects meta-analysis of the prevalence of *Y. enterocolitica* by (a) age and gender of participants and season of sampling and (b) biotypes and serotypes.



FIGURE 6: Metaregression results between the prevalence of *Y. enterocolitica* and (a) publication year of the culture studies; (b) publication year of the molecular studies; (c) human development index of the culture studies; (d) human development index of the molecular studies; (e) longitude of the countries of the culture studies; (f) longitude of the countries of molecular studies; (g) latitudes of the countries of the culture studies.

from children, whereas *Y. enterocolitica* serotype O9 was frequently isolated from adults (\geq 40 years of age). Exposure of children to *Y. enterocolitica* O3 may conceivably provide

some immunity against acute infections due to the same serotype during their life, but not necessarily from other serotypes [65]. According to HDI, the prevalence of Y. enterocolitica was increased with the decrease of HDI that can be related to a higher level of hygienic standards in these countries. In the current study, latitude had a different effect on the prevalence of Y. enterocolitica in culture and molecular diagnosis. Y. enterocolitica is a psychrotrophic bacterium and can replicate in cooler climates [59]. A study on seroprevalence of Y. enterocolitica in wild boars showed that the prevalence was higher in cold climates [70]. Similar results were seen in pigs [71]. The viable organisms were detected in the culture method, but in PCR, the not viable ones were also detected which may be the reason for the higher prevalence of Y. enterocolitica in the temperate zone in the molecular diagnosis compared to culture. The range of prevalence was narrow in the current study which may be the reason for different observations in culture and PCR method, although, in culture, it was not significant.

4.1. Strengths and Limitations. This was the first systematic review and meta-analysis to gain a global prevalence of Y. enterocolitica in gastroenteritis patients. We considered both the culture and PCR isolation of the organism. There was high heterogeneity among the studies especially due to income but mostly reduced by the application of subgroup analysis and metaregression. Additionally, this study has some limitations that must be acknowledged: first, in some analyses, the number of included studies was low, especially in the older ages (e.g., >60 years); second, there were not sufficient related studies for assessing risk factors; third, the age of participants was not reported clearly in some included studies. Forth, the transmission method of the organism was not reported in the studies. However, estimating the global prevalence of Y. enterocolitica is challenging as most of the studies were performed in hospitalized patients with gastrointestinal symptoms. We encourage further studies, especially in the western Pacific and southeast WHO regions to produce and share local data about yersiniosis. An update of our study should be done due to the availability of additional data.

5. Conclusion

In conclusion, the findings of this systematic review show that *Y. enterocolitica* is prevalent in gastroenteritis in all age groups. *Y. enterocolitica* was not prevalent in high-income countries and countries with higher HDI values. Serotypes O3 and O9 of *Y. enterocolitica* had the highest prevalence and O5,27 had the least prevalence in diarrheal patients. The prevalence of *Y. enterocolitica* was similar in both gender and different seasons. It should be noted that to determine the role of the organism, more studies are needed especially in food-borne diseases.

Abbreviations

<i>Y. enterocolitica</i> :	Yersinia enterocolitica
PRISMA:	Preferred Reporting Items for Systematic
	Reviews and Meta-Analyses
TZ:	Tayebeh Zeinali
SMR:	Seyed Mohamad Riahi

EA:	Ehsan Ahmadi
HDI:	Human development index
WHO:	World Health Organization
SD:	Standard deviation
PCR:	Polymerase chain reaction
Fig:	Figure
USA:	United States of America.

Data Availability

The data are available from the corresponding author on reasonable request.

Ethical Approval

The study was approved by the ethical committee of Birjand University of Medical Sciences (Ir.bums.rec.1399.176).

Conflicts of Interest

The authors declare that there are no conflicts of interest about the results of the present study.

Authors' Contributions

SMR, EA, and TZ designed the research. SMR, EA, and TZ conducted the meta-analysis and drafted the manuscript. SMR and TZ analyzed the data. SMR, EA, and TZ revised the manuscript. All the authors read and approved the final manuscript.

Acknowledgments

The authors acknowledge the research and technology deputy of Birjand University of Medical Sciences for support of this study (Grant no. 5434).

Supplementary Materials

The search strategy is presented in the supplementary material. (*Supplementary Materials*)

References

- A. E. J. Okwori, P. O. Martínez, M. Fredriksson-Ahomaa, S. E. Agina, and H. Korkeala, "Pathogenic Yersinia enterocolitica 2/O:9 and Yersinia pseudotuberculosis 1/O:1 strains isolated from human and non-human sources in the Plateau State of Nigeria," *Food Microbiology*, vol. 26, no. 8, pp. 872–875, 2009.
- [2] E. J. Bottone, "Yersinia enterocolitica: revisitation of an enduring human pathogen," Clinical Microbiology Newsletter, vol. 37, no. 1, pp. 1–8, 2015.
- [3] R. Duan, J. Liang, J. Zhang et al., "Prevalence of Yersinia enterocolitica Bioserotype 3/O:3 among children with Diarrhea, China, 2010–2015," *Emerging Infectious Diseases*, vol. 23, no. 9, pp. 1502–1509, 2017.
- [4] M. Bucher, C. Meyer, B. Grötzbach, S. Wacheck, A. Stolle, and M. Fredriksson-Ahomaa, "Epidemiological data on pathogenic Yersinia enterocolitica in southern Germany during 2000–2006," Foodborne Pathogens and Disease, vol. 5, no. 3, pp. 273–280, 2008.

- [5] M. Fredriksson-Ahomaa, A. Stolle, and H. Korkeala, "Molecular epidemiology of *Yersinia enterocolitica* infections," *FEMS Immunology and Medical Microbiology*, vol. 47, no. 3, pp. 315–329, 2006.
- [6] K. Nikolaou, A. Hensel, C. Bartling et al., "Prevalence of anti-Yersinia outer protein antibodies in goats in lower saxony," *Journal of Veterinary Medicine Series B*, vol. 52, no. 1, pp. 17–24, 2005.
- [7] S. Boqvist, H. Pettersson, Å. Svensson, and Y. Andersson, "Sources of sporadic Yersinia enterocolitica infection in children in Sweden, 2004: a case-control study," *Epidemiology* and Infection, vol. 137, no. 6, pp. 897–905, 2008.
- [8] L. A. Lee, J. Taylor, G. P. Carter, B. Quinn, J. J. Farmer, and R. V. Tauxe, "Yersinia enterocolitica O: 3: an emerging cause of pediatric gastroenteritis in the United States," *Journal of Infectious Diseases*, vol. 163, no. 3, pp. 660–663, 1991.
- [9] H. Zheng, Y. Sun, S. Lin, Z. Mao, and B. Jiang, "Yersinia enterocolitica infection in diarrheal patients," European Journal of Clinical Microbiology & Infectious Diseases, vol. 27, no. 8, pp. 741–752, 2008.
- [10] Z. Munn, S. Moola, D. Riitano, and K. Lisy, "The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence," *International Journal of Health Policy and Management*, vol. 3, no. 3, pp. 123–128, 2014.
- [11] M. F. Freeman and J. W. Tukey, "Transformations related to the angular and the square root," *The Annals of Mathematical Statistics*, vol. 21, no. 4, pp. 607–611, 1950.
- [12] R. Harris, M. Bradburn, J. Deeks, R. Harbord, D. Altman, and J. Sterne, "Metan: fixed-and random-effects meta-analysis," *STATA Journal*, vol. 8, no. 3, 2008.
- [13] S. M. Riahi and Y. Mokhayeri, "Methodological issues in a meta-analysis," *Current Medical Research and Opinion*, vol. 33, no. 10, p. 1813, 2017.
- [14] J. Higgins, Assessing Risk of Bias in Included Studies, D. G. Altman and J. P. T. Higgins, Eds., UK: The Cochrane Collaboration, Wiley-Blackwell, Chichester, UK, 2008.
- [15] Y. Mokhayeri, S. M. Riahi, S. Rahimzadeh, M. A. Pourhoseingholi, and S. S. Hashemi-Nazari, "Metabolic syndrome prevalence in the Iranian adult's general population and its trend: a systematic review and meta-analysis of observational studies," *Diabetes & Metabolic Syndrome: Clinical Research Reviews*, vol. 12, no. 3, pp. 441–453, 2018.
- [16] A. Calderaro, M. Martinelli, M. Buttrini et al., "Contribution of the FilmArray gastrointestinal panel in the laboratory diagnosis of gastroenteritis in a cohort of children: a two-year prospective study," *International Journal of Medical Microbiology*, vol. 308, no. 5, pp. 514–521, 2018.
- [17] Y. A. Hawash, K. A. Ismail, and M. Almehmadi, "High frequency of enteric Protozoan, viral, and bacterial potential pathogens in community-acquired acute diarrheal episodes: evidence based on results of luminex gastrointestinal pathogen panel assay," *Korean Journal of Parasitology*, vol. 55, no. 5, pp. 513–521, 2017.
- [18] X. Wang, J. Wang, H. Sun et al., "Etiology of childhood infectious diarrhea in a developed region of China: compared to childhood diarrhea in a developing region and adult diarrhea in a developed region," *PLoS One*, vol. 10, no. 11, Article ID e0142136, 2015.
- [19] K. Fiedoruk, T. Daniluk, D. Rozkiewicz et al., "Conventional and molecular methods in the diagnosis of community-acquired diarrhoea in children under 5 years of age from the north-eastern region of Poland," *International Journal of Infectious Diseases*, vol. 37, pp. 145–151, 2015.

- [20] F. E. A. Assis, S. Wolf, M. Surek et al., "Impact of Aeromonas and diarrheagenic *Escherichia coli* screening in patients with diarrhea in Paraná, southern Brazil," *The Journal of Infection in Developing Countries*, vol. 8, no. 12, pp. 1609–1614, 2014.
- [21] I. Hilmarsdóttir, G. E. Baldvinsdóttir, H. Harðardóttir, H. Briem, and S. I. Sigurðsson, "Enteropathogens in acute diarrhea: a general practice-based study in a Nordic country," *European Journal of Clinical Microbiology & Infectious Dis*eases, vol. 31, no. 7, pp. 1501–1509, 2012.
- [22] I. A. El Qouqa, M. A. E. Jarou, A. S. A. Samaha, A. S. A. Afifi, and A. M. K. Al Jarousha, "Yersinia enterocolitica infection among children aged less than 12 years: a case-control study," *International Journal of Infectious Diseases*, vol. 15, no. 1, pp. e48–e53, 2011.
- [23] X. Wang, Z. Cui, H. Wang et al., "Pathogenic strains of Yersinia enterocolitica isolated from domestic dogs (Canis familiaris) belonging to farmers are of the same subtype as pathogenic Y. enterocolitica strains isolated from humans and may Be a source of human infection in Jiangsu province, China," Journal of Clinical Microbiology, vol. 48, no. 5, pp. 1604–1610, 2010.
- [24] H. C. Maltezou, A. Zafiropoulou, M. Mavrikou et al., "Acute diarrhoea in children treated in an outpatient setting in Athens, Greece," *Journal of Infection*, vol. 43, no. 2, pp. 122–127, 2001.
- [25] S. Huhulescu, R. Kiss, M. Brettlecker et al., "Etiology of acute gastroenteritis in three sentinel general practices," *Infection*, vol. 37, no. 2, pp. 103–108, 2007.
- [26] D. C. Bublitz, P. C. Wright, J. R. Bodager, F. T. Rasambainarivo, J. B. Bliska, and T. R. Gillespie, "Epidemiology of pathogenic enterobacteria in humans, livestock, and peridomestic rodents in rural Madagascar," *PLoS One*, vol. 9, no. 7, Article ID e101456, 2014.
- [27] A. Ehara, K. Egawa, F. Kuroki, O. I. a. M. Okawa, and M. Okawa, "Age-dependent expression of abdominal symptoms in patients with *Yersinia enterocolitica* infection," *Pediatrics International*, vol. 42, no. 4, pp. 364–366, 2000.
- [28] A. Ternhag, A. Törner, A. Svensson, K. Ekdahl, and J. Giesecke, "Short- and long-term effects of bacterial gastrointestinal infections," *Emerging Infectious Diseases*, vol. 14, no. 1, pp. 143–148, 2008.
- [29] C. Gijsbers, M. Benninga, and H. Büller, "Clinical and laboratory findings in 220 children with recurrent abdominal pain," *Acta Paediatrica*, vol. 100, no. 7, pp. 1028–1032, 2011.
- [30] J. R. Rees, M. A. Pannier, A. McNees, S. Shallow, F. J. Angulo, and D. J. Vugia, "Persistent diarrhea, arthritis, and other complications of enteric infections: a pilot survey based on California FoodNet surveillance, 1998–1999," *Complications* of Enteric Infections, vol. 38, no. 3, pp. S311–S317, 2004.
- [31] L. Vernacchio, R. M. Vezina, A. A. Mitchell, S. M. Lesko, A. G. Plaut, and D. W. K. Acheson, "Diarrhea in American infants and young children in the community setting," *The Pediatric Infectious Disease Journal*, vol. 25, no. 1, pp. 2–7, 2006.
- [32] D. A. Talan, G. J. Moran, M. Newdow et al., "Etiology of bloody diarrhea among patients presenting to United States emergency departments: prevalence of *Escherichia coli* O157: H7 and other enteropathogens," *Clinical Infectious Diseases*, vol. 32, no. 4, pp. 573–580, 2001.
- [33] M. A. S. de Wit, M. P. G. Koopmans, L. M. Kortbeek, N. J. van Leeuwen, J. Vinje, and Y. T. H. P. van Duynhoven, "Etiology of gastroenteritis in sentinel general practices in the

Netherlands," Clinical Infectious Diseases, vol. 33, pp. 280-288, 2001.

- [34] C. Karsten, S. Baumgarte, A. W. Friedrich et al., "Incidence and risk factors for community-acquired acute gastroenteritis in north-west Germany in 2004," *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 28, no. 8, pp. 935–943, 2009.
- [35] B. Svenungsson, A. Lagergren, E. Ekwall et al., "Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases," *Clinical Infectious Diseases*, vol. 30, no. 5, pp. 770–778, 2000.
- [36] B. Olesen, J. Neimann, B. Böttiger et al., "Etiology of diarrhea in young children in Denmark: a case-control study," *Journal of Clinical Microbiology*, vol. 43, no. 8, pp. 3636– 3641, 2005.
- [37] M. I. Sinclair, M. E. Hellard, R. Wolfe, T. Z. Mitakakis, K. Leder, and C. K. Fairley, "Pathogens causing community gastroenteritis in Australia," *Journal of Gastroenterology and Hepatology*, vol. 20, no. 11, pp. 1685–1690, 2005.
- [38] A. Jansen, K. Stark, J. Kunkel et al., "Aetiology of communityacquired, acute gastroenteritis in hospitalised adults: a prospective cohort study," *BMC Infectious Diseases*, vol. 8, no. 1, p. 143, 2008.
- [39] A. E. J. Okwori, G. O. A. Agada, A. O. Olabode, S. E. Agina, E. S. Okpe, and J. Okopi, "The prevalence of pathogenic *Yersinia enterocolitica* among diarrhea patients in Jos, Nigeria," *African Journal of Biotechnology*, vol. 6, no. 8, pp. 1031–1034, 2007.
- [40] A. I. Omoigberale and P. O. Abiodun, "Prevalence of *Yersinia enterocolitica* among diarrhoeal patients attending university of Benin teaching hospital, Benin city, Nigeria," *Sahel Medical Journal*, vol. 5, no. 4, pp. 182–185, 2002.
- [41] N. M. Abdel-Haq, R. Papadopol, B. Asmar, and W. Brown, "Antibiotic susceptibilities of *Yersinia enterocolitica* recovered from children over a 12-year period," *International Journal of Antimicrobial Agents*, vol. 27, no. 5, pp. 449–452, 2006.
- [42] C. Perdikogianni, E. Galanakis, M. Michalakis et al., "Yersinia enterocolitica infection mimicking surgical conditions," Pediatric Surgery International, vol. 22, no. 7, pp. 589–592, 2006.
- [43] H. Zheng, J. Wang, Y. Sun, and B. Jiang, "Clinical isolation and characterization of *Yersinia enterocolitica* in China using real-time PCR and culture method," *Digestion*, vol. 75, no. 4, pp. 199–204, 2007.
- [44] N. J. Gasco, M. Vargas, D. Schellenberg, H. Urassa, C. Casals, and E. Kahigwa, "Diarrhea in children under 5 years of age from Ifakara, Tanzania: a case-control study," *Journal of Clinical Microbiology*, vol. 38, no. 12, pp. 4459–4462, 2000.
- [45] R. Stephan, S. Joutsen, E. Hofer et al., "Characteristics of Yersinia enterocolitica biotype 1A strains isolated from patients and asymptomatic carriers," European Journal of Clinical Microbiology & Infectious Diseases, vol. 32, no. 7, pp. 869–875, 2013.
- [46] E. Garveriani, M. M. Aslani, S. Habibzadeh, and A. Fathi, "Role of *Yersinia enterocolitica* in acute diarrhea of childern under 5 years old in cold seasons in Ardabil," *Journal of Ardabil University of Medical Sciences*, vol. 7, no. 4, pp. 387–391, 2008.
- [47] F. GhasemiKebria, B. Khodabakhshi, H. Kouhsari, M. SadeghiSheshpoli, N. Behnampoor, and S. Livani, "Yersinia enterocolitica in cases of diarrhea in Gorgan, northern Iran," Medical Laboratory Journal, vol. 4, no. 1, 2010.
- [48] A. M. K. Al Jarousha, M. A. El Jarou, and I. A. El Qouqa, "Bacterial enteropathogens and risk factors associated with

childhood diarrhea," *Indian Journal of Pediatrics*, vol. 78, no. 2, pp. 165–170, 2011.

- [49] E. Huovinen, L. M. Sihvonen, K. Haukka, A. Siitonen, M. Kuusi, and M. Kuusi, "Symptoms and sources of *Yersinia enterocolitica*-infection: a case-control study," *BMC Infectious Diseases*, vol. 10, no. 1, p. 122, 2010.
- [50] L. M. Sihvonen, K. Haukka, K. Haukka, M. Kuusi, M. J. Virtanen, and A. Siitonen, "Yersinia enterocolitica and Y. enterocolitica-like species in clinical stool specimens of humans: identification and prevalence of bio/serotypes in Finland," European Journal of Clinical Microbiology & Infectious Diseases, vol. 28, no. 7, pp. 757–765, 2009.
- [51] P. P. Orlandi, T. Silva, G. F. Magalhães et al., "Enteropathogens associated with diarrheal disease in infants of poor urban areas of Porto Velho, Rondônia: a preliminary study," *Memórias do Instituto Oswaldo Cruz*, vol. 96, no. 5, pp. 621–625, 2001.
- [52] N. M. Abdel-Haq, B. I. Asmar, W. M. Abuhammour, and W. J. Brown, "Yersinia enterocolitica infection in children," *The Pediatric Infectious Disease Journal*, vol. 19, no. 10, pp. 954–958, 2000.
- [53] L. F. Nimri and M. Meqdam, "Enteropathogens associated with cases of gastroenteritis in a rural population in Jordan," *Clinical Microbiology and Infections*, vol. 10, no. 7, pp. 634– 639, 2004.
- [54] S. Maraki, A. Georgiladakis, Y. Tselentis, and G. Samonis, "A 5-year study of the bacterial pathogens associated with acute diarrhoea on the island of Crete, Greece, and their resistance to antibiotics," *European Journal of Epidemiology*, vol. 18, pp. 85–90, 2003.
- [55] M. E. Torres, M. C. Pirez, F. Schelotto et al., "Etiology of children's diarrhea in montevideo, Uruguay: associated pathogens and unusual isolates," *Journal of Clinical Microbiology*, vol. 39, no. 6, pp. 2134–2139, 2001.
- [56] M. M. Dallal, M. R. Khorramizadeh, and K. MoezArdalan, "Occurrence of enteropathogenic bacteria in children under 5 years with diarrhoea in south Tehran," *Eastern Mediterranean Health Journal*, vol. 12, no. 6, pp. 792–797, 2006.
- [57] M. M. Soltan-Dallal and K. Moezardalan, "Frequency of Yersinia species infection in paediatric acute diarrhoea in Tehran," *Eastern Mediterranean Health Journal*, vol. 10, no. 1, pp. 152–158, 2004.
- [58] A. A. Soleymani-Rahbar, F. Fayaz, A. Zargarizadeh, and R. Nikazma, "Surveying the prevalence and pattern of antimicrobial resistance of *Yersinia enterocolitica* among diarrheal children attending health care centers in Qom," *Iranian Journal of Clinical Infectious Diseases*, vol. 2, no. 3, pp. 143– 147, 2007.
- [59] N. Drummond, B. P. Murphy, T. Ringwood, M. B. Prentice, J. F. Buckley, and S. Fanning, "Yersinia enterocolitica: a brief review of the issues relating to the zoonotic pathogen, public health challenges, and the pork production chain," Foodborne pathogens and disease, vol. 9, no. 3, pp. 179–189, 2012.
- [60] A. Chakraborty, K. Komatsu, M. Roberts et al., "The descriptive epidemiology of yersiniosis: a multistate study, 2005–2011," *Public Health Reports*, vol. 130, no. 3, pp. 269–277, 2015.
- [61] Foodborne Diseases Active Surveillance Network (FoodNet), "Incidence and trends of infection with pathogens transmitted commonly through food —foodborne diseases active surveillance Network, 10 U.S. Sites, 1996–2012," *Morbidity and Mortality Weekly Report*, vol. 62, no. 15, pp. 283–287, 2013.

- [62] (ECDC) European Centre for Disease Prevention and Control Yersiniosis, ECDC Annual Epidemiological Report for 2016, ECDC, Stockholm, Sweden, 2018.
- [63] M. Fredriksson-Ahomaa, N. Lindstrom, and H. Korkeala, Pathogens and Toxins in Food: Challenges and Interventions, ASM Press, Washington, DC, USA, 2010.
- [64] A. Rahman, T. S. Bonny, S. Stonsaovapak, and C. Ananchaipattana, "Yersinia enterocolitica: epidemiological studies and outbreaks," *Journal of Pathogens*, vol. 2011, Article ID 239391, 11 pages, 2011.
- [65] B. M. Rosner, K. Stark, and D. Werber, "Epidemiology of reported Yersinia enterocolitica infections in Germany, 2001–2008," BMC Public Health, vol. 10, no. 1, p. 337, 2010.
- [66] S. M. Ray, S. D. Ahuja, P. A. Blake, M. M. Farley, M. Samuel, and T. Rabatsky-Ehr, "Population-based surveillance for yersiniaenterocolitica infections in FoodNet sites, 1996–1999: higher risk of disease in infants and minority populations," *Clinical Infectious Diseases*, vol. 38, no. 3, pp. 181–189, 2004.
- [67] (ECDC) European Centre for Disease Prevention and Control, Surveillance Report: Annual Epidemiological Report on Communicable Diseases in Europe 2010, (ECDC) European Centre for Disease Prevention and Control, Stockholm, Sweden, 2010.
- [68] M. M. Soltan-Dallal, "Diarrhea caused by enteropathogenic bacteria in children," *Archives of Iranian Medicine*, vol. 4, no. 4, pp. 201–203, 2001.
- [69] N. Bhagat and J. S. Virdi, "The Enigma of Yersinia enterocolitica biovar 1A," Critical Reviews in Microbiology, vol. 37, no. 1, pp. 25–39, 2011.
- [70] M. Arrausi-Subiza, X. Gerrikagoitia, V. Alvarez, J. C. Ibabe, and M. Barra, "Prevalence of *Yersinia enterocolitica* and Yersinia pseudotuberculosis in wild boars in the Basque Country, northern Spain," *Acta Veterinaria Scandinavica*, vol. 58, no. 4, 2016.
- [71] J. Liang, X. Wang, Y. Xiao et al., "Prevalence of Yersinia enterocolitica in pigs slaughtered in Chinese abattoirs," Applied and Environmental Microbiology, vol. 78, no. 8, pp. 2949–2956, 2012.